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Abstract 
Background: Blood glucose variability is receiving considerable attention as a new risk factor for coronary artery 
disease. This study aimed to investigate the association between blood glucose variability and coronary plaque tissue 
characteristics.
Methods: In 57 patients with acute coronary syndrome, integrated backscatter intravascular ultrasound (IB-IVUS) and 
gray-scale IVUS were performed before balloon dilatation or stent implantation in the culprit vessels. Standard IVUS 
indices were evaluated for volume index (volume/length), and plaque components were measured by IB-IVUS for 
percent tissue volume. In addition to conventional glucose indicators, blood glucose variability in a stable state was 
determined by calculating the mean amplitude of glycemic excursions (MAGE) using a continuous glucose monitor-
ing system.
Results: Higher MAGE values were significantly correlated with larger percent plaque volumes (r = 0.32, p = 0.015), 
and increased lipid (r = 0.44, p = 0.0006) and decreased fibrous (r = −0.45, p = 0.0005) plaque components. In 
contrast, HbA1c or fasting plasma glucose values were not significantly correlated with plaque volumes and percent 
plaque components. Homeostasis model assessment of insulin resistance values were positively correlated with ves-
sel (r = 0.35, p = 0.007) and plaque (r = 0.27, p = 0.046) volumes, but not with percent plaque components. In multi-
ple regression analysis, higher MAGE values were independently associated with increased lipid (β = 0.80, p = 0.0035) 
and decreased fibrous (β = -0.79, p = 0.0034) contents in coronary plaques.
Conclusions: Among all glucose indicators studied, only higher blood glucose variability was an independent 
determinant of increased lipid and decreased fibrous contents with larger plaque burden, suggesting blood glucose 
variability as one of the important factors related to coronary plaque vulnerability.
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Background
Glycemic disorder is an important risk factor of coronary 
plaque progression and instability, and subsequent acute 
coronary syndromes (ACS) [1–7]. While previous studies 
focused primarily on hemoglobin A1c (HbA1c), fasting 
plasma glucose (FPG), homeostasis model assessment of 
insulin resistance (HOMA-IR), advanced glycation end 
products (AGEs), and glucagon-like peptide 1 (GLP-1) to 
assess the severity of diabetes-related vascular complica-
tions [1–5], blood glucose variability has been recognized 
as another important measure in recent investigations 
[8–10]. Continuous glucose monitoring system (CGMS) 
can directly visualize blood glucose variability, offering a 
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more sensitive method to detect the variety of glycemic 
disorder compared to other conventional glucose indica-
tors (HbA1c, FPG, HOMA-IR) [11].
Previous CGMS studies of patients with diabetes mel-
litus (DM) have shown that blood glucose variability 
was more strongly associated with atherogenic factors, 
such as oxidative stress, endothelial dysfunction and 
inflammation compared to sustained hyperglycemia rep-
resented as HbA1c and FPG [8, 9, 12]. Hence, it is reason-
able to hypothesize that the assessment of blood glucose 
variability using CGMS may more accurately measure the 
severity of diabetes-related vascular disease (in particu-
lar, atherosclerotic plaques) compared to conventional 
glucose indicators. Therefore, the aims of this study are 
to characterize blood glucose variability as measured by 
CGMS and to investigate its association with coronary 
tissue characteristics in patients with ACS.
Methods
Study population
This was a prospective, observational study of ACS 
patients admitted to Yokohama City University Medical 
Center. ACS patients who underwent both percutane-
ous coronary intervention (PCI) with integrated back-
scatter (IB) intravascular ultrasound (IVUS) guidance 
in the culprit vessel and CGMS measurement were eli-
gible for enrollment. Patients with renal dysfunction 
(serum creatinine >2.0 mg/dl at admission) or receiving 
insulin (for both type 1 and type 2 DM) were excluded. 
ACS consisted of ST-segment elevation myocardial 
infarction (STEMI) and non ST-segment elevation ACS 
(NSTE-ACS). STEMI was defined as the presence of 
anginal symptoms (>20  min) associated with electro-
cardiographic ST-segment elevation of at least 0.1  mV 
in two or more limb leads or at least 0.2  mV in two or 
more precordial leads, and a rise in cardiac-specific tro-
ponin I values. NSTE-ACS included non ST-segment 
elevation myocardial infarction (NSTEMI) and unsta-
ble angina pectoris. NSTEMI was defined as ischemic 
symptoms in the absence of ST elevation on electrocar-
diogram with elevated cardiac-specific troponin I values. 
Unstable angina pectoris was defined as having newly 
developed and accelerated chest symptoms on exertion 
or rest angina without a significant rise in cardiac-spe-
cific troponin I values. DM was determined by the fol-
lowing criteria: medical history, FPG value of ≥126 mg/
dl; casual plasma glucose value of ≥200  mg/dl; or dia-
betic pattern based on 75-g oral glucose tolerance tests 
(OGTT). OGTT was performed in a stable condition (at 
12 ±  5  days) during hospital admission. The study pro-
tocol was approved by the Institutional Review Board 
at Yokohama City University Medical Center, and every 
patient provided written informed consent.
CGMS
All CGMS monitoring was performed in a stable condi-
tion without any treatment with anti-diabetic drugs dur-
ing hospital admission (at 10 ±  6  days) to minimize the 
influence of ACS and anti-diabetic medications on CGMS 
monitoring: inflammation caused by ACS had peaked; 
and patients had regular meals and were ambulatory [13]. 
Study patients were equipped with a fourth-generation 
CGMS (iPro2, Medtronic, USA) and were monitored for 
24 consecutive hours. Patients received three energy-con-
trolled meals per day during CGMS monitoring. A CGMS 
sensor was inserted into the subcutaneous abdominal fat 
tissue. Ipro2 uses a retrospective algorithm to convert 
sensor signals to glucose levels based on self-monitoring 
of capillary blood glucose readings; therefore, blood glu-
cose values were checked at least four times per day using 
the finger-stick test. Blood glucose variability was deter-
mined by the mean amplitude of glycemic excursions 
(MAGE) based on the CGMS data [12]. MAGE values 
were calculated by measuring the arithmetic mean of dif-
ferences between consecutive peaks and nadirs, provid-
ing that the differences were greater than one standard 
deviation (SD) of the mean blood glucose value; measure-
ments in the peak-to-nadir or nadir-to-peak directions 
were determined by the first qualifying excursion. In this 
study, significant hyperglycemia and significant hypogly-
cemia were defined as a blood glucose value of ≥200 and 
<60 mg/dl, respectively [14, 15].
Laboratory evaluation
In addition to CGMS parameters, conventional glucose 
indicators (HbA1c, FPG, HOMA-IR), lipid variables 
[total cholesterol (TC), low-density lipoprotein cho-
lesterol (LDL-C), high-density lipoprotein cholesterol 
(HDL-C), triglycerides], high-sensitive C-reactive pro-
tein (hs-CRP) values, and estimated glomerular filtration 
rate (eGFR) were evaluated. While HbA1c, lipid variables 
and eGFR values were measured at admission, FPG and 
HOMA-IR (at 12 ± 5 days), and hs-CRP (at 7 days) val-
ues were measured in a stable condition during hospital 
admission. eGFR values were determined from serum 
creatinine values, using the prediction equation proposed 
by the Japanese Society of Nephrology. HOMA-IR values 
were mathematically calculated by the formula: [fasting 
plasma glucose (FPG, mg/dl) ×  fasting immunoreactive 
insulin (IRI, μU/ml)/405] [2]. Urinary liver-type fatty 
acid-binding protein (L-FABP) values in 52 patients were 
also measured in the first morning urine on the day after 
admission as an indirect marker of oxidative stress [16].
IVUS procedure
Coronary angiography was performed via the femoral 
or radial approach. Heparin (5000–10,000 units) was 
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administered intravenously before PCI, and periproce-
dural intravenous heparin was administered to maintain 
an activated clotting time ≥250 s. Intracoronary isosorb-
ide dinitrate (ISDN) was also administered before angi-
ography to prevent coronary artery spasm. IVUS imaging 
was performed using a mechanical IVUS system with a 
40-MHz, 5 Fr imaging catheter (VISIWAVE with ViewIT. 
Terumo, Tokyo, Japan) before balloon dilation or stent 
implantation [2, 4, 6, 17]. Thrombus aspiration was per-
formed prior to IVUS as necessary. After ISDN adminis-
tration (2–3 mg), the catheter was advanced sufficiently 
distal to the culprit lesion, and automated pullback was 
then performed at 0.5  mm/s. Images were recorded for 
offline analysis of each culprit vessel.
IVUS analysis
Intravascular ultrasound analysis was performed with 
a validated quantitative IVUS analysis system (VISI-
ATLAS, Terumo, Tokyo, Japan) [18] by an experienced 
investigator, blinded to clinical information. Vessel, 
lumen and plaque (vessel minus lumen) areas were man-
ually traced at 1-mm intervals throughout each entire 
culprit vessel (average length analyzed: 66 ± 26 mm), and 
the interpolated measurements of the remaining frames 
were automatically generated [19]. Vessel, lumen and 
plaque volumes were calculated using Simpson’s method 
and standardized as volume index (volume/analyzed 
length, mm3/mm). Percent plaque volume was calculated 
as (plaque volume/vessel volume) × 100 (%). Remodeling 
index was calculated mathematically as vessel area at the 
minimum lumen area site divided by the average vessel 
area of the proximal and distal reference sites [19]. IB 
data for each tissue component were calculated as aver-
age power levels using a fast Fourier transform, measured 
in decibels, of the frequency component of backscattered 
signals from a small volume of tissue. IB-IVUS analysis 
classified the color-coded tissue into four major compo-
nents: blue (lipid); green (fibrosis); yellow (dense fibrosis); 
red (calcification) [2]. Quantitative volumetric IB-IVUS 
analyses were performed to calculate lipid, fibrosis, dense 
fibrosis, and calcification volumes from the sum of lipid, 
fibrosis, dense fibrosis, and calcification areas in each 
cross-sectional area at 1-mm intervals for the IB-IVUS 
images. Percentages of plaque volume were automatically 
calculated as each plaque component volume/plaque vol-
ume × 100 (%). Intra- or interobserver intra-class corre-
lation coefficients (ICC) for the vessel, lumen, and plaque 
areas were 0.999 and 0.999, 0.996 and 0.993, and 0.993 
and 0.991, respectively. The intra- and interobserver ICC 
for the percent lipid and fibrous areas were 0.997 and 
0.996, and 0.996 and 0.995, as we previously reported 
[18].
Statistical analysis
Data are expressed as frequencies and percentages for 
category variables, and as mean ± SD for continuous var-
iables. Categorical comparisons were performed using a 
Chi square test or Fisher’s exact test. Continuous values 
were compared by using unpaired t-test, Mann–Whitney 
U test, or one-way analyses of variance, as appropriate. 
Correlation between continuous variables was evaluated 
by using linear regression analysis. Multiple linear regres-
sion analysis was performed to determine the factors 
associated with percent lipid and fibrous contents of cor-
onary plaques. Factors analyzed were: age; sex; body mass 
index; medical history (diabetes, hyperlipidemia, hyper-
tension, current smoking, type of ACS, culprit vessel, 
presence of mutivessel coronary disease); pre-treatment 
with statins or anti-diabetic drugs before admission; 
conventional glucose indicators (HbA1c, FPG, HOMA-
IR); CGMS indices (MAGEA, mean, maximum, and 
minimum blood glucose values, episodes of significant 
hyperglycemia ≥200  mg/dl and hypoglycemia <60  mg/
dl); lipid variables (TC, LDL-C, HDL-C, triglycerides); 
hs-CRP; and eGFR values. Variables with p-value ≤0.15 
on univariable analysis were entered into the multivaria-
ble model. A p-value of <0.05 was considered statistically 
significant. Statistical calculations were performed with 
JMP® 10 (SAS Institute Inc., Cary, NC, USA).
Results
Patient characteristics
A total of 76 consecutive patients with ACS who met 
the inclusion and exclusion criteria and underwent 
both IB-IVUS and CGMS examinations were enrolled 
in this study. Nineteen were excluded because of poor-
quality IVUS images (5 patients), stent thrombosis (1 
patient), no IVUS imaging before PCI (5 patients), or 
insufficient CGMS data for analysis (8 patients). As a 
result, 57 data from 57 patients were analyzed. As seen 
in Table  1, the average age was 65 ±  12  years, and the 
majority of patients were men. The proportion of STEMI 
was 77.2  % and DM was 49.1  %. HbA1c and FPG val-
ues were 6.1 ±  1.0 % and 109 ±  17 mg/dl, respectively. 
HOMA-IR values (insulin resistance) were 2.1 ± 1.4. The 
percentage of patients treated with statins before admis-
sion was 21.1  % and LDL-C values at admission were 
128 ± 36 mg/dl.
CGMS parameters
Continuous glucose monitoring system data include 
a mean blood glucose value of 126  ±  27  mg/dl and 
MAGE (blood glucose variability) value of 48 ± 26 mg/
dl (Table  1). During CGMS monitoring, blood glucose 
values largely remained within the range of 90–200 mg/
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dl, as recommended by the guideline [14]; however, vari-
ous glucose variability patterns were seen, irrespective of 
glucose metabolism (normal glucose tolerance, impaired 
glucose tolerance, type 2 DM). In addition, asymptomatic 
hyperglycemia and hypoglycemia were found in some 
patients. Significant hyperglycemia (≥200  mg/dl) was 
seen in 29.8 % of the patients. Significant hypoglycemia 
(<60 mg/dl) was found in 7.0 % of patients. The incidence 
of hypoglycemia did not differ significantly between 
patients with and without DM (7.1 vs. 6.9 %, p = 0.97), 
and all hypoglycemia were seen in patients without treat-
ment with anti-diabetic drugs before admission. Figure 1 
shows a representative case of CGMS monitoring where 
sustained postprandial hyperglycemia was more promi-
nent toward the evening meal and significant hypoglyce-
mia (54 mg/dl) was found at night despite conventional 
glucose indicators being within normal range.
In terms of relationships among CGMS parameters, 
MAGE values were significantly correlated with maxi-
mum blood glucose values (r  =  0.88, p  <  0.0001) and 
mean blood glucose values (r  =  0.55, p  <  0.0001), but 
not significantly with minimum blood glucose values 
(r =  0.05, p =  0.70). When study patients were divided 
into two groups based on the median value of MAGE, 
proportions of significant hyperglycemia (≥200  mg/dl) 
(57.1 vs. 3.5 %, p < 0.0001) and hypoglycemia (<60 mg/
dl) (14.3 vs. 0 %, p = 0.014) were found to be greater in 
patients with higher blood glucose variability compared 
to those with lower blood glucose variability.
Relationships between conventional glucose indicators 
and CGMS parameters
HbA1c and FPG were positively correlated with maxi-
mum blood glucose, minimum blood glucose, mean 
blood glucose, and MAGE values, while HOMA-IR val-
ues were not (Table 2). In the categorical analyses (higher 
or lower than each median value of conventional glu-
cose indicators), significant hyperglycemia (≥200  mg/
dl) was more frequent in patients with higher HbA1c 
(53.6 vs. 6.9 %, p < 0.0001) or higher FPG (50.0 vs. 10.3 %, 
p = 0.0007) values compared to those with lower HbA1c 
or FPG values, whereas the incidence of significant hypo-
glycemia (<60 mg/dl) did not differ significantly between 
the higher and lower groups (3.6 vs. 10.3 %, p = 0.31 for 
both HbA1c and FPG). There was also no significant dif-
ference in hyperglycemia (28.6 vs. 32.1  %, p =  0.77) or 
hypoglycemia (3.6 vs. 10.7 %, p = 0.29) between patients 
with higher and lower HOMA-IR values.
Relationships of glucose indicators to oxidative stress 
and inflammation
Urinary L-FABP values were significantly correlated with 
MAGE values (r = 0.37, p = 0.008) and tended to corre-
late with HOMA-IR values (r = 0.27, p = 0.054), but not 
with HbA1c (r = 0.05, p = 0.74) or FPG values (r = 0.09, 
p  =  0.53). On the other hand, hs-CRP values tended 
to correlate with MAGE values (r  =  0.25, p  =  0.066), 
but not with conventional glucose indicators (HbA1c: 
Table 1 Clinical characteristics and CGMS parameters
ACEI/ARB angiotensin-converting enzyme inhibitor and/or angiotensin II 
receptor blocker, CGMS continuous glucose monitoring system, eGFR estimated 
glomerular filtration ratio, FPG fasting plasma glucose, HDL-C high-density 
lipoprotein cholesterol, HOMA-IR homeostasis model assessment of insulin 
resistance, LDL-C low-density lipoprotein cholesterol, MAGE mean amplitude of 
glucose excursion, STEMI ST-segment elevation myocardial infarction, L-FABP 
liver-type fatty acid-binding protein (in the first morning urine on the day after 
admission)
a Measured in a stable condition during hospital admission
Variables All (n = 57)
Age (years) 65 ± 12
Male (%) 78.9
Body mass index (kg/m2) 24.2 ± 4.1
STEMI (%) 77.2
Multivessel disease (%) 35.1
Culprit vessel
 Left anterior descending artery (%) 52.6
 Left circumflex coronary artery (%) 14.0
 Right coronary artery (%) 33.3
Current smoking (%) 54.4
Hypertension (%) 61.4
Diabetes mellitus (%) 49.1
Lipid parameters at admission
 Total cholesterol (mg/dl) 201 ± 37
 LDL-C (mg/dl) 128 ± 36
 HDL-C (mg/dl) 46 ± 12
 Triglycerides (mg/dl) 129 ± 96
eGFR at admission (ml/min/1.73 m2) 75.2 ± 18.2
Urinary L-FABP (μg/g creatinine) 20.3 ± 58.0
hs-CRP at 7 days after admission (mg/dl) 1.56 ± 1.72
Medications before admission
 Statin (%) 21.1
 ACEI/ARB (%) 21.1
 Oral anti-diabetic drugs (%) 17.5
Conventional glucose indicators
 HbA1c at admission (%) 6.1 ± 1.0
 FPGa (mg/dl) 109 ± 17
 HOMA-IRa 2.1 ± 1.4
CGMS parametersa
 Maximum blood glucose (mg/dl) 184 ± 48
 Minimum blood glucose (mg/dl) 90 ± 21
 Mean blood glucose (mg/dl) 126 ± 27
 SD around mean blood glucose (mg/dl) 22 ± 12
 MAGE (blood glucose variability) (mg/dl) 48 ± 26
 Hyperglycemia ≥200 mg/dl (%) 29.8
 Hypoglycemia <60 mg/dl (%) 7.0
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r = −0.05, p = 0.71; FPG: r = 0.004, p = 0.98; HOMA-IR: 
r = −0.04, p = 0.77).
Factors associated with gray‑scale IVUS indices
Mean amplitude of glycemic excursions (blood glucose 
variability) values were positively correlated with plaque 
volumes, percent plaque volumes and remodeling index 
(r = 0.27, p = 0.046), and tended to correlate with ves-
sel volumes (Fig. 2). In contrast, mean blood glucose val-
ues as measured by CGMS (vessel volumes: r = −0.09, 
p  =  0.51; lumen volumes: r  =  −0.07, p  =  0.58; plaque 
volumes: r = −0.08, p =  0.56; percent plaque volumes: 
r = 0.06, p = 0.63; remodeling index: r = 0.20, p = 0.15) 
or HbA1c values (Fig.  3; remodeling index: r  =  0.21, 
p = 0.13) were not correlated with any gray-scale IVUS 
indices. FPG values were correlated with remodeling 
index (r  =  0.33, p  =  0.013), but not with other IVUS 
indices (Fig.  4). HOMA-IR values were correlated with 
vessel, lumen and plaque volumes, but not with percent 
plaque volumes (Fig. 5) or remodeling index (r = −0.05, 
p  =  0.71). Patients with significant hyperglycemia 
(≥200  mg/dl) tended to have greater plaque burden 
compared to those without (61.6 ± 10.4 vs. 56.3 ± 8.9 %, 
p  =  0.053). Patient with significant hypoglycemia 
(<60  mg/dl) also had greater percent plaque volume 
compared to those without (69.4 ± 9.6 vs. 57.0 ± 9.1 %, 
p = 0.011). While MAGE values were significantly higher 
in patients with DM compared to those without (60 ± 26 
vs. 37  ±  22  mg/dl, p  =  0.0003), gray-scale IVUS indi-
ces were comparable between the two groups (Table 3). 
LDL-C or hs-CRP value was not significantly correlated 
with any gray-scale IVUS indices.
Factors associated with percent lipid and fibrous volumes
Mean amplitude of glycemic excursions values were posi-
tively correlated with percent lipid volumes (%LV) and 
negatively with percent fibrous volumes (%FV) (Fig. 2). In 
contrast, conventional glucose indicators (HbA1c, FPG, 
HOMA-IR), and mean blood glucose values as measured 
by CGMS were not significantly correlated with %LV or 
%FV (Figs. 3, 4, 5; Tables 4, 5). Patients with significant 
hyperglycemia tended to have higher %LV (62.4 ±  11.5 
vs. 57.4 ± 10.5 %, p = 0.12) and lower %FV (33.3 ± 9.6 
vs. 37.3 ±  8.1  %, p =  0.12) compared to those without. 
Patients with significant hypoglycemia also had numeri-
cally higher %LV (66.3 ± 6.9 vs. 58.3 ± 11.0 %, p = 0.16) 
and lower %FV (30.3 ±  5.9 vs. 36.5 ±  8.8  %, p =  0.17) 
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Fig. 1 Representative case of CGMS monitoring. Patient was a 59-year-old man who was diagnosed with STEMI. He had medical history of hyper-
tension, hyperlipidemia and current smoking, and was diagnosed with impaired glucose tolerance on OGTT during hospital admission. Conven-
tional glucose indicators were within normal range: however, CGMS monitoring revealed sustained postprandial hyperglycemia that was more 
prominent toward the evening meal, and significant hypoglycemia at night. MBG mean blood glucose, FPG fasting plasma glucose
Table 2 Correlations between conventional glucose indicators and CGMS parameters
Abbreviations shown in Table 1
Variables (mg/dl) HbA1c (%) FPG (mg/dl) HOMA‑IR
MAGE (glucose variability) r = 0.36 p = 0.0065 r = 0.47, p = 0.0002 r = −0.07, p = 0.59
Mean blood glucose r = 0.63, p < 0.0001 r = 0.84, p < 0.0001 r = −0.0003, p = 0.998
Maximum blood glucose r = 0.48, p = 0.0002 r = 0.69, p < 0.0001 r = −0.05, p = 0.73
Minimum blood glucose r = 0.57, p < 0.0001 r = 0.60, p < 0.0001 r = 0.07, p = 0.61
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reach statistical significance. On the other hand, the 
presence of DM, treatment with statins or anti-diabetic 
drugs before admission, LDL-C or hs-CRP value was 
not associated with plaque components (Tables  4, 5). 
Although MAGE values were significantly higher in 
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Fig. 3 Correlations between hemoglobin A1c and IVUS indices
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(53 ± 27 vs. 34 ± 17 mg/dl, p = 0.03), the type of ACS 
(STEMI or NSTE-ACS) was not associated with plaque 
components (Tables 4, 5).
Significant correlations of MAGE values with plaque 
instability were found in the subgroup analyses (Table 6). 
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Fig. 4 Correlations between fasting plasma glucose and IVUS indices
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Fig. 5 Correlations between HOMA-IR and IVUS indices
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with plaque instability were seen when we excluded the 
10-mm length segment centered at the minimum lumen 
area (MLA) site in the culprit vessel from the origi-
nal analyses to minimize influence of thrombus around 
the culprit lesion (%LV: r  =  0.41, p  =  0.0014;   %FV: 
r = −0.41, p = 0.0017). In the multiple regression analy-
sis including all variables with p-value of ≤0.15 on uni-
variable analysis, only MAGE values were independently 
associated with both increased %LV and decreased %FV 
(Tables 4, 5). Higher MAGE value was also an independ-
ent risk factor for increased %LV and decreased %FV in 
multivariable analysis including LDL-C (%LV: β =  0.84, 
p  =  0.0026; %FV: β  =  −0.83, p  =  0.0025) or urinary 
L-FABP (%LV: β  =  0.63, p  =  0.026; %FV: β  =  −0.62, 
p  =  0.026) in the original model, whereas LDL-C and 
urinary L-FABP values were not significantly associated 
with plaque components.
Discussion
The main findings of this study are: (1) higher blood 
glucose variability was more strongly associated with 
increased lipid and decreased fibrous contents with 
larger plaque burden and higher remodeling index in 
the culprit vessels of ACS as compared to conventional 
glucose indicators (HbA1c, FPS, HOMA-IR); and (2) 
higher blood glucose variability was an independent 
risk factor for plaque instability. Higher blood glucose 
variability was also more closely linked with the mark-
ers of oxidative stress and inflammation as compared to 
conventional glucose indicators. Our findings suggest 
the potential utility of the assessment of blood glucose 
variability using CGMS in the prediction of vulnerable 
plaques, and indicate the underlying mechanisms of the 
association between higher blood glucose variability and 
coronary plaque instability.
Table 3 Gray-scale IVUS and IB-IVUS indices
DM diabetes mellitus
* p-values for DM vs. non-DM









14.3 ± 4.6 14.4 ± 4.7 14.2 ± 4.7 0.89
Lumen volume 
(mm3/mm)
5.9 ± 2.1 5.8 ± 2.1 6.0 ± 2.1 0.68
Plaque volume 
(mm3/mm)
8.4 ± 3.3 8.6 ± 3.1 8.2 ± 3.5 0.51
Percent plaque 
volume (%)
57.9 ± 9.6 59.3 ± 8.9 56.6 ± 10.1 0.29
Remodeling 
index
1.08 ± 0.17 1.10 ± 0.16 1.05 ± 0.17 0.27
Lipid volume 
(mm3/mm)
5.1 ± 2.6 5.3 ± 2.5 4.9 ± 2.7 0.45
Fibrous volume 
(mm3/mm)
2.9 ± 0.9 2.9 ± 0.9 2.9 ± 1.0 0.96
Percent lipid 
volume (%)
58.9 ± 10.9 59.7 ± 11.6 58.1 ± 10.4 0.57
Percent fibrous 
volume (%)
36.1 ± 8.7 35.2 ± 8.9 37.0 ± 8.5 0.44
Table 4 Factors associated with percent lipid volumes
Abbreviations shown in Table 1
Variables Univariable Multivariable
r p value β p value
Age (years) 0.26 0.055 0.13 0.30
STEMI 0.05 0.73
Statin before admission −0.07 0.57
Anti-diabetic drugs before 
admission
0.18 0.18
LDL-C (mg/dl) −0.17 0.21
HDL-C (mg/dl) 0.24 0.07 0.14 0.26
hs-CRP (mg/dl) 0.16 0.24
eGFR (ml/min/1.73 m2) −0.19 0.16
HbA1c (%) −0.02 0.86
FPG (mg/dl) −0.02 0.88
HOMA-IR 0.02 0.90
MAGE (glucose variability) 
(mg/dl)
0.44 0.0006 0.80 0.0035
Mean blood glucose (mg/dl) 0.001 0.99
Maximum blood glucose 
(mg/dl)
0.29 0.03 −0.25 0.44
Hyperglycemia (≥200 mg/dl) 0.21 0.12 −0.25 0.28
Hypoglycemia (<60 mg/dl) 0.19 0.16
Table 5 Factors associated with percent fibrous volume
Abbreviations shown in Table 1
Variables Univariable Multivariable
r p value β p value
Age (years) −0.27 0.04 −0.14 0.25
STEMI −0.03 0.80
Statin before admission 0.08 0.56
Anti-diabetic drugs before  
admission
−0.19 0.16
LDL-C (mg/dl) 0.18 0.19
HDL-C (mg/dl) −0.27 0.04 −0.17 0.17
hs-CRP (mg/dl) −0.19 0.153
eGFR (ml/min/1.73 m2) 0.16 0.25
HbA1c (%) 0.05 0.73
FPG (mg/dl) 0.02 0.87
HOMA-IR −0.004 0.97
MAGE (glucose variability) (mg/dl) −0.45 0.0005 −0.79 0.0034
Mean blood glucose (mg/dl) 0.002 0.99
Maximum blood glucose (mg/dl) −0.29 0.03 0.24 0.44
Hyperglycemia (≥200 mg/dl) −0.21 0.12 0.26 0.27
Hypoglycemia (<60 mg/dl) −0.18 0.17
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Vulnerable plaque as assessed by IB‑IVUS
Previous studies have demonstrated that disruption or 
erosion of vulnerable plaques and subsequent thrombus 
formation are the most frequent causes of ACS [20]. Lipid 
incorporation into the arterial wall is a key player in the 
initiation and progression of atherosclerosis, and lipid-
rich plaque is associated with coronary plaque instability, 
an important determinant of spontaneous plaque rup-
ture [2, 6, 21]. In the pathologic study assessing vulner-
able plaque after ACS, larger lipid core is recognized as 
the marker for plaque vulnerability [21]. In the IB-IVUS 
study evaluating plaque morphology before the occur-
rence of ACS [22], the percent lipid area was greater and 
percent fibrous area was smaller in coronary plaques that 
caused ACS than in those without ACS. Another study 
has reported that higher percent lipid area and lower per-
cent fibrous area were associated with thin-cap fibroath-
eroma as evaluated by optical coherence tomography 
(OCT) [23]. These findings suggest that increased lipid 
and decreased fibrous contents in coronary plaques can 
be good indicators of vulnerable plaques.
Blood glucose variability
In the present study, we found that among all the glu-
cose indicators studied, only higher blood glucose vari-
ability (MAGE values) was an independent determinant 
of plaque instability in the culprit vessel of ACS. Previous 
studies have reported that blood glucose variability as 
measured by CGMS was more strongly associated with 
atherogenic factors, such as oxidative stress, inflamma-
tion, and endothelial dysfunction compared to sustained 
hyperglycemia represented as HbA1c and FPG [8, 9, 12, 
24]. All these factors link with coronary plaque instabil-
ity. In particular, oxidative stress plays a pivotal role in 
diabetic vascular disease, and modulates the expression 
of matrix metalloproteinases (MMPs) and the forma-
tion of oxidative LDL [25, 26]. MMPs may contribute 
to plaque vulnerability by degrading the components 
of the fibrous cap [25]. Oxidative LDL is involved in 
atherogenesis, such as induction of adhesion protein 
expression and subsequent entry of mononuclear cells, 
formation of foam cells, and apoptosis and necrosis of 
vascular smooth muscle cells, inducing formation of the 
necrotic/lipid core [27]. Coronary endothelial dysfunc-
tion and inflammation are also associated with lipid-rich 
plaque or plaque morphology [28, 29]. Therefore, in the 
present study, the fact that only blood glucose variability 
correlated or tended to correlate with both markers of 
oxidative stress (urinary L-FABP values) and inflamma-
tion (hs-CRP values) as compared to conventional glu-
cose indicators may attribute to its stronger association 
with coronary plaque instability.
When the culprit vessels excluding the culprit lesion 
(segment of 10-mm length centered at MLA site) were 
analyzed, a significant correlation of higher blood glucose 
variability with plaque instability was also found in the 
present study. Teraguchi et  al. [13] have suggested that 
higher blood glucose variability is associated with coro-
nary plaque vulnerability in the culprit lesion of AMI. 
In addition, Asakura et  al. [30] previously reported the 
pan-coronary process of vulnerable plaque development 
in patients with MI. Our findings can add important 
insights to their findings: higher blood glucose variabil-
ity links closely with both coronary plaques that lead to 
plaque rupture and non-culprit plaques.
Conventional glucose indicators and lipid parameters
In contrast to previous IB-IVUS studies in which conven-
tional glucose indicators (HbA1c, FPG, HOMA-IR) were 
associated with coronary plaque instability (increased 
lipid and decreased fibrous contents) [2, 3], the current 
study failed to show the significant association of these 
glucose indicators with plaque instability. In addition to 
the weaker correlations of sustained hyperglycemia with 
atherogenic factors discussed above, one possible rea-
son for this discrepancy may be insufficient accuracy of 
conventional glucose indicators to measure the variety of 
glycemic disorder. Unlike the previous studies targeting 
Table 6 Subgroup analyses of relationships between blood glucose variability and percent lipid and fibrous volume
Abbreviations shown in Table 1
Subgroup Percent lipid volumes Percent fibrous volumes
DM r = 0.29, p = 0.13 r = −0.26, p = 0.18
Non DM r = 0.67, p < 0.0001 r = −0.68, p < 0.0001
STEMI r = 0.41, p = 0.006 r = −0.41, p = 0.006
NSTE-ACS r = 0.73, p = 0.005 r = −0.76, p = 0.003
No treatment with statins before admission r = 0.50, p = 0.0005 r = −0.51, p = 0.0004
No treatment with anti-diabetic drugs before admission r = 0.50, p = 0.0004 r = −0.50, p = 0.0004
LDL-C ≥140 mg/dl r = 0.48, p = 0.02 r = −0.51, p = 0.01
LDL-C <140 mg/dl r = 0.44, p = 0.01 r = −0.42, p = 0.01
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patients with type 2 DM or impaired glucose tolerance 
alone [2, 3], our study population included various glyce-
mic metabolism (normal glucose tolerance, impaired glu-
cose tolerance, type 2 DM). HbA1c and FPG are mainly 
the indicators of chronic sustained hyperglycemia; there-
fore, the relative contribution of acute glucose fluctuation 
(postprandial hyperglycemia, hypoglycemia) to glucose 
disorder may not be exactly reflected in them [11, 31, 
32]. Both postprandial hyperglycemia and hypoglycemia 
are important risk factors for cardiovascular disease, and 
have been reported to be associated with atherogenic fac-
tors, such as increased oxidative stress, inflammation and 
sympathetic nerve activity [33, 34]. Hence, glucose indi-
cators reflecting both hyperglycemia and hypoglycemia, 
such as blood glucose variability, may be reasonable to 
evaluate glycemic disorder. The accuracy of HOMA-IR 
for predicting insulin resistance is also limited in subjects 
with higher FPG and lower beta cell function [35]. Thus, 
in this small population with various glycemic metabo-
lism, conventional glucose indicators alone may not be 
sufficiently sensitive in reflecting the variety of glycemic 
disorder and thereby failed to show their significant asso-
ciation with coronary plaque instability.
Increased LDL-C value is a well-established risk fac-
tor for cardiovascular events and vulnerable plaques 
[36]; however, the present study failed to show significant 
correlation between LDL-C value and plaque instability. 
Several possible explanations for this may be proposed. 
First, our study included patients with both controlled 
(pre-treated with statins) and uncontrolled dyslipidemia, 
thereby potentially affecting our findings. Second, 49.1 % 
of the study patients had DM. Previous studies have 
shown that proportions of LDL particle size were dif-
ferent between patients with and without DM: small 
dense LDL (sd-LDL) particles are significantly higher in 
patients with DM [37]. Although we did not measure sd-
LDL values, the assessment of LDL particle size may be 
able to reveal more clearly the link between dyslipidemia 
and plaque instability, because increased sd-LDL value is 
a stronger predictor for cardiovascular events compared 
to LDL-C value [38].
Limitations
Several limitations should be noted in this study. First, 
this is a primarily hypothesis-generating, observational 
study with small sample size at a single center. Second, 
patients with severe glycemic disorder (i.e. patients 
treated with insulin) were excluded from this study. 
Although diabetes-related macrovascular disease can 
occur, even in the early stages of glycemic disorder, our 
findings will need to be confirmed in further investiga-
tions with larger sample size, including patients with 
severe glycemic disorder. Third, some patients were 
treated with anti-atherosclerotic drugs, such as statins 
and anti-diabetic drugs before admission. When ana-
lyzed separately, patients without pre-treatment with 
these drugs had similar results. While Kuroda et al. [10] 
have also reported the association between blood glucose 
variability and plaque instability in patients with CAD 
pre-treated with lipid-lowering therapy, the influence 
of these drugs should be sufficiently investigated in the 
future. Fourth, there may have been the potential influ-
ence of thrombus and vessel shrinkage on IVUS analy-
ses because this study targeted culprit vessels of ACS. 
Fifth, increased lipid and decreased fibrous contents 
in the plaque have been reported to be associated with 
thin-cap fibroatheroma [23]; however, the association 
between blood glucose variability and fibrous cap thick-
ness (another important measure to evaluate vulner-
able plaque) remains unknown. Finally, it also remains 
unknown whether blood glucose variability in an acute 
phase and in a stable condition are similarly predictive 
for plaque instability. Furthermore, whether the assess-
ment of intra- and inter-day blood glucose variability in 
a non-hospital setting could offer additional predictive 
value ought to be clarified.
Conclusion
The current study revealed that compared to conven-
tional glucose indicators (HbA1c, FPG, HOMA-IR), 
higher blood glucose variability as measured by CGMS 
was independently and more strongly associated with 
increased lipid and decreased fibrous contents with 
larger plaque burden and higher remodeling index in the 
culprit vessel of ACS patients. Our findings suggest that 
the assessment of blood glucose variability using CGMS 
may contribute to better prediction of vulnerable plaque, 
thus, blood glucose variability may become a new thera-
peutic target for the prevention of ACS in patients with 
coronary artery disease.
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